25 results about "Hyperinsulinemia" patented technology

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

Treatment of hyperinsulinemic hypoglycemia comprises administration of an effective amount of a glucagon-like peptide-1 receptor antagonist (GLPIRA) alone or in combination with an amylinomimetic agent or any anti-gastric emptying agent. Patients suffering from hyperinsulinemic hypoglycemia after bariatric surgery experience particular benefit, as there is no current method effective for their treatment. Prevention or reduction of acute adverse effects of postprandial hypoglycemia, such as palpitations, tremor, weakness, sweating, confusion, fatigue, blurred vision, seizures, or loss of consciousness, and prevention of chronic adverse effects of hyperinsulinemic hypoglycemia, such as cognitive impairment, can be achieved by treatment with GLP1RA.

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

The invention provides a pharmaceutical composition for preventing and treating metabolic syndrome, resisting islet injury and promoting gastrointestinal function. The pharmaceutical composition is an oral preparation prepared from traditional Chinese medicinal raw materials or raw material extracts according to the following weight ratio. The raw material composition comprises the following medicinal materials and decoction pieces in parts by weight: 6-60 parts of fenugreek and 6-60 parts of inula flower. The traditional Chinese medicine composition comprises the following raw material extracts in parts by weight: 1-20 parts of fenugreek extract and 1-25 parts of inula flower extract. The pharmaceutical composition disclosed by the invention can effectively reduce blood sugar, triglyceride and cholesterol, improve insulin tolerance and hyperinsulinemia, improve glucose tolerance, relieve pancreas islet injury and promote gastrointestinal motility. The composition is good in safety, can be clinically used for preventing and treating the metabolic syndrome and protecting pancreas islet in the early stage, and can also be used for treating gastric paralysis and constipation.

Polypeptide antagonists of the human insulin receptor are provided. In some embodiments, a pharmaceutical formulation is provided, comprising an INSR antagonist as identified herein, and a pharmaceutically acceptable excipient. The formulation may be provided in a unit dose, e.g. a therapeutically effective dose. In methods of the disclosure, an effective dose of a an INSR antagonist as identified herein is administered to an individual having, or at risk of having, hyperinsulinemia, in a dose effective to stabilize, reduce or prevent clinical symptoms of the disease. The individual may be monitored for clinical indicia of disease before, during, and / or after administration.

The present disclosure relates generally to high concentration formulations comprising an anti-insulin receptor antibody RZ358 and their use in the treatment of hyperinsulinemia disorders.

Provided herein are methods and materials for treating or reducing the risk of obesity and / or conditions associated with obesity (e.g., type 2 diabetes or hyperinsulinemia). For example, provided herein are methods and materials for inhibiting RalA to treat obesity and / or conditions associated with obesity in a subject in need thereof. In some cases, the subject has elevated expression of RalA compared to a healthy individual.

The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Embodiments of this invention relate to the binding fragments of antibodies described herein, comprising the sequences of the VH, VL and / or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-ACTH antibodies and binding fragments thereof for the diagnosis, assessment, prevention and treatment of diseases and disorders associated with ACTH, such as CAH, FGD, Cushing's Disease, Cushing's Syndrome, Parkinson's disease, obesity, diabetes, sleep disorders, depression, anxiety disorders, cancer, muscle atrophy, hypertension, hyperinsulinemia, cognitive dysfunction, Alzheimer's disease, galactorrhea, stress related conditions, cardiac conditions, metabolic syndrome, hyperaldosteronism, Conn's syndrome and familial hyperaldosteronism.

The application is a bifunctional cyclic peptide which reduces insulin and does not increase blood sugar but appropriately reduces blood sugar, and belongs to the technical field of biological medicine. 52‑69 The cyclic peptide is obtained by in-vitro modification and reformation on the basis of the original linear short peptide COX The application realizes the seemingly contradictory two aspects of functions, i.e. inhibiting insulin secretion while not increasing blood sugar, and even reducing blood sugar, and the mechanism may be that the sensitivity of the tissue to insulin is improved. We call it a bifunctional peptide. The bifunctional peptide can be used for congenital hyperinsulinemia, insulin resistance, high insulin of obese people, etc. Literature reports that the increase of insulin is the cause of obesity, but for a long time, we cannot reduce weight by reducing insulin because the blood sugar will increase after the reduction of insulin, and high blood sugar is more harmful to health. The cyclic peptide realizes the function of reducing insulin while the blood sugar does not increase, but is reduced, which opens up a new way for weight loss of obesity, and the peptide can be conveniently administered orally in addition to injection. The convenience of use is greatly improved.

Hyperinsulinemia is a pathogenesis basis of coronary heart disease, hypertension, hyperlipidemia, type II diabetes and obesity, and is also one of reasons for complications of the coronary heart disease, hypertension, hyperlipidemia, type II diabetes and obesity. At present, no good coping method exists. The invention discloses an oligopeptide with activity of inhibiting glucose-induced insulin secretion. The polypeptide COX52-69 with the function of inhibiting insulin secretion is subjected to gradual truncation and functional experiments, a key active fragment which still keeps the function of inhibiting insulin secretion is screened, and the sequence of the key active fragment is LPAGWVLSHLDS (namely a continuous fragment obtained after amino acid is gradually removed from the sequence of the original polypeptide COX52-69, and the key active fragment is called COX53-64). Experiments show that the novel oligopeptide fragment can still inhibit glucose-induced insulin secretion in an in-vitro model. The novel oligopeptide provided by the invention has fewer amino acids and is easier to synthesize and modify, so that the cost is saved to a greater extent, and the novel oligopeptide can be applied to development of drugs for treating hyperinsulin and metabolic disorder related diseases caused by hyperinsulin.

The present invention relates to novel GLP-1 receptor antagonist analogs and acylated GLP-1 receptor analogs and their use for the prevention or treatment of congenital hyperinsulinemia or hypoglycemia.

The invention provides an application of AQP1 in preparation of a medicine for treating hyperinsulinemia myocardial injury, and relates to the field of biomedicine.The AQP1 protein serves as a target spot and is inhibited by using a related inhibitor, so that myocardial edema is effectively reduced, ion homeostasis unbalance is improved, mitochondrial dysfunction is repaired, and the effect of treating hyperinsulinemia myocardial injury is achieved. Therefore, the effect of treating the hyperinsulinemia myocardial injury is achieved.

This invention discloses a method, system, medium, and device for weight loss and muscle preservation health management suitable for individuals with hyperinsulinemia and obesity, belonging to the field of health management technology. The method and system provided by this invention for weight loss and muscle preservation health management in individuals with hyperinsulinemia and obesity involves standardized and structured collection, screening, and verification of the target user's health data to provide accurate and standardized data input for subsequent algorithm processing. Based on the processed health data, a muscle mass classification algorithm is used to automate and standardize the classification of the user's muscle mass, improving the accuracy of the classification. Then, based on the muscle mass classification results, a multi-model fusion algorithm is used to calculate precise and personalized protein intake standards for users with different muscle masses. Combined with an integrated drug matching algorithm, standardized matching recommendations for GLP-1 drug use are output. Finally, the drug matching recommendations and protein intake plan are synergistically linked to generate a structured health management technical report for users to directly implement, avoiding a disconnect between user nutrition management and drug use. This achieves synergy between muscle mass protection and adequate protein intake, ultimately helping users achieve precise and efficient health management.

The present invention provides a liquid pharmaceutical formulation comprising exendin (9-39) or a pharmaceutically acceptable salt thereof and a tonicity adjusting agent in a physiologically acceptable buffer having a pH ranging from about 5 to about 6. In some embodiments, the liquid pharmaceutical formulation comprises exendin (9-39) or a pharmaceutically acceptable salt thereof in an acetate buffer or a citrate buffer. Also provided are methods of treating or preventing hyperinsulinemic hypoglycemia in a subject, the method comprising administering the liquid pharmaceutical formulation to the subject.

The present disclosure relates to modulators and / or antagonists of the insulin-insulin receptor signaling complex, as well as methods for selecting such modulators and / or antagonists. Such modulators and / or antagonists can be used to treat mammalian subjects suffering from, or to prevent the onset of, disease states and conditions characterized by, for example, type 2 diabetes, obesity, hyperglycemia, hyperinsulinemia, insulin overdose, chronic kidney disease, type 1 diabetes, insulin resistance, and insulin resistance. The present disclosure provides novel modulators and / or antagonists of the insulin-insulin receptor signaling complex, methods for selecting such modulators and / or antagonists, and disease states and conditions characterized by abnormally increased production and / or utilization of insulin. Use of such modulators and / or antagonists for the treatment or prevention of endogenous hyperinsulinism, preferably congenital hyperinsulinism (CHI), is also provided.

The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the VH, VL and / or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-ACTH antibodies and binding fragments thereof for the diagnosis, assessment, prevention and treatment of diseases and disorders associated with ACTH, such as Cushing's Disease, Cushing's Syndrome, Parkinson's disease, obesity, diabetes, sleep disorders depression, anxiety disorders, cancer, muscle atrophy, hypertension, hyperinsulinemia, cognitive dysfunction, Alzheimer's disease, galactorrhea, stress related conditions, cardiac conditions, metabolic syndrome, hyperaldosteronism, Conn's syndrome and familial hyperaldosteronism.

Provided herein are liquid pharmaceutical formulations comprising exendin (9-39) or a pharmaceutically acceptable salt thereof and a tonicity modifier in a physiologically acceptable buffer having a pH in the range of about 5 to about 6. In some embodiments, the buffered liquid formulation comprises exendin (9-39) or a pharmaceutically acceptable salt thereof in an acetate buffer or a citrate buffer. Methods of treating or preventing hyperinsulinemic hypoglycemia in a subject comprising administering to the subject the buffered liquid formulation are also provided.

The application provides an application of AQP1 in preparation of a drug for treating hyperinsulinemic myocardial injury, relates to the field of biological medicines, and uses an inhibitor related to the AQP1 protein as a target to inhibit the AQP1 protein, thereby effectively reducing myocardial edema, improving ion homeostasis imbalance and repairing mitochondrial dysfunction, so that the effect of treating hyperinsulinemic myocardial injury is achieved.

The present disclosure relates to compounds of general formula (I) or pharmaceutically acceptable salts, solvates and / or hydrates thereof, processes for their preparation, the use of the compounds as medicaments, and their use in the treatment and / or prophylaxis of diseases or disorders such as metabolic disorders, such as hyperinsulinemia, such as congenital hyperinsulinemia. The present disclosure also relates to pharmaceutical compositions comprising a compound of general formula (I) and a pharmaceutically acceptable carrier and their use as a medicament, in particular their use in the treatment of a disease or condition, such as a metabolic condition, such as hyperinsulinemia, such as congenital hyperinsulinemia.

The present disclosure relates, in general, to formulations comprising anti-insulin receptor antibody RZ 358 and use thereof to treat hyperinsulinemia disorders.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a mangnolia officinalis extract or a structural analogue thereof in preparation of a medicament for treating hyperinsulinemia / hyperamminemia syndrome. The invention provides a new application of a mangnolia officinalis extract represented by honokiol. Research shows that the mangnolia officinalis extract or the structural analogue thereof can well inhibit the activity of glutamate dehydrogenase (GDH), including wild type GDH and GDH capable of causing acquisition function mutation of the hyperinsulinemia / hyperamminemia (HI / HA) syndrome, so that the effect of the mangnolia officinalis extract or the structural analogue thereof as a GDH inhibitor in treatment of the HI / HA syndrome is expanded, and the application of the mangnolia officinalis extract or the structural analogue thereof in treatment of the HI / HA syndrome is promoted. Effective attempts are made for solving the problem that existing medicines for treating the rare HI / HA syndrome are rare, the current situation of treating the HI / HA syndrome can be remarkably improved, the situation of lack of targeted medicines is broken through, the life quality of patients is improved, and the family and social burden of the patients is greatly relieved.

Provided herein are GLP-1 receptor antagonist peptides and pharmaceutical compositions for treating hypoglycemia. Also provided herein are methods of treating atypical hypoglycemia in patients with hyperinsulinemia, including patients who have become hyperinsulinemic after bariatric surgery.

The present invention relates to compositions and methods for treating metabolic disorders. Bromocriptine citrate administered to a vertebrate, animal, or human can be used for any purpose including, for example, long-term alteration and modulation of metabolic disorders including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia, and type 2 diabetes (T2DM); and / or other medical conditions including, for example, immune or endocrine disorders or diseases. Bromocriptine citrate is administered for a limited or extended period of time in a day depending on the normal circadian rhythm of the central dopaminergic activity of healthy members rebuilding similar species and genders. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS, or all, can be controlled in humans on a long-term basis by such treatment as the daily administration of bromocriptine citrate resets the timing of neuronal activity in the nerve center of the brain, resulting in a long-term effect.

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.